Antibody data
- Antibody Data
- Antigen structure
- References [70]
- Comments [0]
- Validations
- Western blot [3]
- Immunocytochemistry [1]
- Immunohistochemistry [1]
- Other assay [6]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MA5-13304 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Estrogen Receptor alpha Monoclonal Antibody (6F11)
- Antibody type
- Monoclonal
- Antigen
- Recombinant full-length protein
- Description
- MA5-13304 has successfully been used in IHC, IP, and Western blot procedures. Paraffin sections require an antigen retrieval pretreatment with sodium citrate buffer (pH 6.0) prior to staining. Use Samboni’s fixative for optimal staining results. Positive control of Breast carcinoma suggested.
- Reactivity
- Human, Rat
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- 6F11
- Vial size
- 500 µL
- Concentration
- Conc. Not Determined
- Storage
- 4° C
Submitted references RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer.
RSK2 Maintains Adult Estrogen Homeostasis by Inhibiting ERK1/2-Mediated Degradation of Estrogen Receptor Alpha.
Detection and analysis of multiple biomarkers in ovarian cancer: clinical significance in diagnosis, treatment, and prognosis evaluation.
NF1 deficiency correlates with estrogen receptor signaling and diminished survival in breast cancer.
Identification of the potential molecular mechanism and driving mutations in the pathogenesis of familial intestinal gastric cancer by whole exome sequencing.
Expression of calcium pumps is differentially regulated by histone deacetylase inhibitors and estrogen receptor alpha in breast cancer cells.
Mammary fibroblasts reduce apoptosis and speed estrogen-induced hyperplasia in an organotypic MCF7-derived duct model.
Silencing of syndecan-binding protein enhances the inhibitory effect of tamoxifen and increases cellular sensitivity to estrogen.
Serum SDF-1 levels are a reliable diagnostic marker of feline mammary carcinoma, discriminating HER2-overexpressing tumors from other subtypes.
A Novel Combinatorial Epigenetic Therapy Using Resveratrol and Pterostilbene for Restoring Estrogen Receptor-α (ERα) Expression in ERα-Negative Breast Cancer Cells.
St Gallen molecular subtypes in feline mammary carcinoma and paired metastases-disease progression and clinical implications from a 3-year follow-up study.
Serum HER2 levels are increased in cats with mammary carcinomas and predict tissue HER2 status.
Neoplastic transformation of porcine mammary epithelial cells in vitro and tumor formation in vivo.
Tissue biomarkers in prognostication of serous ovarian cancer following neoadjuvant chemotherapy.
Unraveling the regulatory connections between two controllers of breast cancer cell fate.
Progesterone and estrogen receptors in conjunctival melanoma and nevi.
Characterization of estrogen response element binding proteins as biomarkers of breast cancer behavior.
Breast cancer tissue slices as a model for evaluation of response to rapamycin.
Comparison of the PharmDx immunohistochemical system with standard methods for assessing estrogen and progesterone receptors in invasive carcinoma of the breast.
Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer.
Genomic and phenotypic profiles of two Brazilian breast cancer cell lines derived from primary human tumors.
Malignant transformation of adenomyoepithelioma of the breast by a monophasic population: a report of two cases and review of literature.
Lowering oral contraceptive norethindrone dose increases estrogen and progesterone receptor levels with no reduction in proliferation of breast epithelium: a randomized trial.
Validation of the aging hen (Gallus gallus domesticus) as an animal model for uterine leiomyomas.
Breast epithelial cell proliferation is markedly increased with short-term high levels of endogenous estrogen secondary to controlled ovarian hyperstimulation.
Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.
Role of Fos-related antigen 1 in the progression and prognosis of ductal breast carcinoma.
Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors.
The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment.
Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers.
HER-2/neu (c-erbB-2) oncoprotein in hyperplastic endometrial polyps detected in two cats.
Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer.
Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH.
EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer.
Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary.
Evaluation of the value of frozen tissue section used as "gold standard" for immunohistochemistry.
Estrogen receptor beta (ERbeta) in endometrial simple hyperplasia and endometrioid carcinoma.
Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas.
The effect of maturation and age on oestrogen-induced functional hypertrophy of the female rabbit bladder.
Altered expression of estrogen receptor alpha and beta in advanced gastric adenocarcinoma: correlation with prothymosin alpha and clinicopathological parameters.
Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation.
Estrogen induced functional hypertrophy and increased force generation of the female rabbit bladder.
Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy.
Overexpression of cyclins D1 and D3 during estrogen-induced breast oncogenesis in female ACI rats.
Antagonist-induced, activation function-2-independent estrogen receptor alpha phosphorylation.
Search for Hsp90 inhibitors with potential anticancer activity: isolation and SAR studies of radicicol and monocillin I from two plant-associated fungi of the Sonoran desert.
The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study.
Abnormal morphology of the penis in male rats exposed neonatally to diethylstilbestrol is associated with altered profile of estrogen receptor-alpha protein, but not of androgen receptor protein: a developmental and immunocytochemical study.
Epithelioid trophoblastic tumor of the broad ligament: a case report and review of the literature.
Epithelioid trophoblastic tumor of the broad ligament: a case report and review of the literature.
Molecular mechanism of estrogen receptor (ER)alpha-specific, estradiol-dependent expression of the progesterone receptor (PR) B-isoform.
The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma.
Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
Simultaneous carcinoma of the endometrium and ovary vs endometrial carcinoma with ovarian metastases: a clinical and immunohistochemical determination.
Simultaneous carcinoma of the endometrium and ovary vs endometrial carcinoma with ovarian metastases: a clinical and immunohistochemical determination.
Characterization of mammary tumor cell lines from wild type and vitamin D3 receptor knockout mice.
Characterization of mammary tumor cell lines from wild type and vitamin D3 receptor knockout mice.
Expression of CYP3A4 in human breast tumour and non-tumour tissues.
Expression of CYP3A4 in human breast tumour and non-tumour tissues.
Breast hamartomas: clinicopathological and immunohistochemical studies of 24 cases.
Breast hamartomas: clinicopathological and immunohistochemical studies of 24 cases.
Immunohistochemical comparison of primary peritoneal and primary ovarian serous papillary carcinoma.
Immunohistochemical comparison of primary peritoneal and primary ovarian serous papillary carcinoma.
5alpha-reductases in human breast carcinoma: possible modulator of in situ androgenic actions.
Biophenotypes and survival of BRCA1 and TP53 deleted breast cancer in young women.
Biophenotypes and survival of BRCA1 and TP53 deleted breast cancer in young women.
Apolipoprotein E polymorphism and breast carcinoma: correlation with cell proliferation indices and clinical outcome.
Apolipoprotein E polymorphism and breast carcinoma: correlation with cell proliferation indices and clinical outcome.
Evidence of an estrogen receptor form devoid of estrogen binding ability in MCF-7 cells.
Evidence of an estrogen receptor form devoid of estrogen binding ability in MCF-7 cells.
Dustin D, Gu G, Beyer AR, Herzog SK, Edwards DG, Lin H, Gonzalez TL, Grimm SL, Coarfa C, Chan DW, Kim BJ, De La O JP, Ellis MJ, Liu D, Li S, Welm AL, Fuqua SAW
British journal of cancer 2021 Jan;124(1):191-206
British journal of cancer 2021 Jan;124(1):191-206
RSK2 Maintains Adult Estrogen Homeostasis by Inhibiting ERK1/2-Mediated Degradation of Estrogen Receptor Alpha.
Ludwik KA, Sandusky ZM, Stauffer KM, Li Y, Boyd KL, O'Doherty GA, Stricker TP, Lannigan DA
Cell reports 2020 Jul 21;32(3):107931
Cell reports 2020 Jul 21;32(3):107931
Detection and analysis of multiple biomarkers in ovarian cancer: clinical significance in diagnosis, treatment, and prognosis evaluation.
Ji R, Li Y, He C, Zhu X, He A, Lu Y
Gland surgery 2020 Dec;9(6):2175-2186
Gland surgery 2020 Dec;9(6):2175-2186
NF1 deficiency correlates with estrogen receptor signaling and diminished survival in breast cancer.
Dischinger PS, Tovar EA, Essenburg CJ, Madaj ZB, Gardner EE, Callaghan ME, Turner AN, Challa AK, Kempston T, Eagleson B, Kesterson RA, Bronson RT, Bowman MJ, Graveel CR, Steensma MR
NPJ breast cancer 2018;4:29
NPJ breast cancer 2018;4:29
Identification of the potential molecular mechanism and driving mutations in the pathogenesis of familial intestinal gastric cancer by whole exome sequencing.
Chen H, Wang J, Zhuang Y, Wu H
Oncology reports 2018 Oct;40(4):2316-2324
Oncology reports 2018 Oct;40(4):2316-2324
Expression of calcium pumps is differentially regulated by histone deacetylase inhibitors and estrogen receptor alpha in breast cancer cells.
Varga K, Hollósi A, Pászty K, Hegedűs L, Szakács G, Tímár J, Papp B, Enyedi Á, Padányi R
BMC cancer 2018 Oct 23;18(1):1029
BMC cancer 2018 Oct 23;18(1):1029
Mammary fibroblasts reduce apoptosis and speed estrogen-induced hyperplasia in an organotypic MCF7-derived duct model.
Morgan MM, Livingston MK, Warrick JW, Stanek EM, Alarid ET, Beebe DJ, Johnson BP
Scientific reports 2018 May 8;8(1):7139
Scientific reports 2018 May 8;8(1):7139
Silencing of syndecan-binding protein enhances the inhibitory effect of tamoxifen and increases cellular sensitivity to estrogen.
Zhang J, Qian X, Liu F, Guo X, Gu F, Fu L
Cancer biology & medicine 2018 Feb;15(1):29-38
Cancer biology & medicine 2018 Feb;15(1):29-38
Serum SDF-1 levels are a reliable diagnostic marker of feline mammary carcinoma, discriminating HER2-overexpressing tumors from other subtypes.
Marques CS, Soares M, Santos A, Correia J, Ferreira F
Oncotarget 2017 Dec 1;8(62):105775-105789
Oncotarget 2017 Dec 1;8(62):105775-105789
A Novel Combinatorial Epigenetic Therapy Using Resveratrol and Pterostilbene for Restoring Estrogen Receptor-α (ERα) Expression in ERα-Negative Breast Cancer Cells.
Kala R, Tollefsbol TO
PloS one 2016;11(5):e0155057
PloS one 2016;11(5):e0155057
St Gallen molecular subtypes in feline mammary carcinoma and paired metastases-disease progression and clinical implications from a 3-year follow-up study.
Soares M, Correia J, Peleteiro MC, Ferreira F
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2016 Mar;37(3):4053-64
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2016 Mar;37(3):4053-64
Serum HER2 levels are increased in cats with mammary carcinomas and predict tissue HER2 status.
Soares M, Ribeiro R, Najmudin S, Gameiro A, Rodrigues R, Cardoso F, Ferreira F
Oncotarget 2016 Apr 5;7(14):17314-26
Oncotarget 2016 Apr 5;7(14):17314-26
Neoplastic transformation of porcine mammary epithelial cells in vitro and tumor formation in vivo.
Rowson-Hodel AR, Manjarin R, Trott JF, Cardiff RD, Borowsky AD, Hovey RC
BMC cancer 2015 Jul 31;15:562
BMC cancer 2015 Jul 31;15:562
Tissue biomarkers in prognostication of serous ovarian cancer following neoadjuvant chemotherapy.
Khandakar B, Mathur SR, Kumar L, Kumar S, Datta Gupta S, Iyer VK, Kalaivani M
BioMed research international 2014;2014:401245
BioMed research international 2014;2014:401245
Unraveling the regulatory connections between two controllers of breast cancer cell fate.
Lee J, Tiwari A, Shum V, Mills GB, Mancini MA, Igoshin OA, Balázsi G
Nucleic acids research 2014 Jun;42(11):6839-49
Nucleic acids research 2014 Jun;42(11):6839-49
Progesterone and estrogen receptors in conjunctival melanoma and nevi.
Bredow L, Stützel L, Böhringer D, Gundlach E, Reinhard T, Auw-Haedrich C
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2014 Feb;252(2):359-65
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2014 Feb;252(2):359-65
Characterization of estrogen response element binding proteins as biomarkers of breast cancer behavior.
Kruer TL, Cummins TD, Powell DW, Wittliff JL
Clinical biochemistry 2013 Nov;46(16-17):1739-46
Clinical biochemistry 2013 Nov;46(16-17):1739-46
Breast cancer tissue slices as a model for evaluation of response to rapamycin.
Grosso SH, Katayama ML, Roela RA, Nonogaki S, Soares FA, Brentani H, Lima L, Folgueira MA, Waitzberg AF, Pasini FS, Góes JC, Brentani MM
Cell and tissue research 2013 Jun;352(3):671-84
Cell and tissue research 2013 Jun;352(3):671-84
Comparison of the PharmDx immunohistochemical system with standard methods for assessing estrogen and progesterone receptors in invasive carcinoma of the breast.
Gill MS, Paish EC, Ronan J, Green AR, Ellis IO, Lee AH
Applied immunohistochemistry & molecular morphology : AIMM 2013 Jan;21(1):90-3
Applied immunohistochemistry & molecular morphology : AIMM 2013 Jan;21(1):90-3
Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer.
Li Y, Meeran SM, Patel SN, Chen H, Hardy TM, Tollefsbol TO
Molecular cancer 2013 Feb 4;12:9
Molecular cancer 2013 Feb 4;12:9
Genomic and phenotypic profiles of two Brazilian breast cancer cell lines derived from primary human tumors.
Corrêa NC, Kuasne H, Faria JA, Seixas CC, Santos IG, Abreu FB, Nonogaki S, Rocha RM, Aparecida Borges Silva G, Gobbi H, Rogatto SR, Goes AM, Gomes DA
Oncology reports 2013 Apr;29(4):1299-307
Oncology reports 2013 Apr;29(4):1299-307
Malignant transformation of adenomyoepithelioma of the breast by a monophasic population: a report of two cases and review of literature.
Marian C, Boila A, Soanca D, Malau M, Podeanu DM, Resetkova E, Stolnicu S
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2013 Apr;121(4):272-9
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2013 Apr;121(4):272-9
Lowering oral contraceptive norethindrone dose increases estrogen and progesterone receptor levels with no reduction in proliferation of breast epithelium: a randomized trial.
Hovanessian-Larsen L, Taylor D, Hawes D, Spicer DV, Press MF, Wu AH, Pike MC, Pearce CL
Contraception 2012 Sep;86(3):238-43
Contraception 2012 Sep;86(3):238-43
Validation of the aging hen (Gallus gallus domesticus) as an animal model for uterine leiomyomas.
Machado SA, Bahr JM, Hales DB, Braundmeier AG, Quade BJ, Nowak RA
Biology of reproduction 2012 Oct;87(4):86
Biology of reproduction 2012 Oct;87(4):86
Breast epithelial cell proliferation is markedly increased with short-term high levels of endogenous estrogen secondary to controlled ovarian hyperstimulation.
Chung K, Hovanessian-Larsen LJ, Hawes D, Taylor D, Downey S, Spicer DV, Stanczyk FZ, Patel S, Anderson AR, Pike MC, Wu AH, Pearce CL
Breast cancer research and treatment 2012 Apr;132(2):653-60
Breast cancer research and treatment 2012 Apr;132(2):653-60
Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.
Joosse SA, Brandwijk KI, Devilee P, Wesseling J, Hogervorst FB, Verhoef S, Nederlof PM
Breast cancer research and treatment 2012 Apr;132(2):379-89
Breast cancer research and treatment 2012 Apr;132(2):379-89
Role of Fos-related antigen 1 in the progression and prognosis of ductal breast carcinoma.
Logullo AF, Stiepcich MM, Osório CA, Nonogaki S, Pasini FS, Rocha RM, Soares FA, Brentani MM
Histopathology 2011 Mar;58(4):617-25
Histopathology 2011 Mar;58(4):617-25
Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors.
Joosse SA, Brandwijk KI, Mulder L, Wesseling J, Hannemann J, Nederlof PM
Genes, chromosomes & cancer 2011 Feb;50(2):71-81
Genes, chromosomes & cancer 2011 Feb;50(2):71-81
The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment.
Bueno-de-Mesquita JM, Nuyten DS, Wesseling J, van Tinteren H, Linn SC, van de Vijver MJ
Annals of oncology : official journal of the European Society for Medical Oncology 2010 Jan;21(1):40-7
Annals of oncology : official journal of the European Society for Medical Oncology 2010 Jan;21(1):40-7
Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers.
Holstege H, van Beers E, Velds A, Liu X, Joosse SA, Klarenbeek S, Schut E, Kerkhoven R, Klijn CN, Wessels LF, Nederlof PM, Jonkers J
BMC cancer 2010 Aug 24;10:455
BMC cancer 2010 Aug 24;10:455
HER-2/neu (c-erbB-2) oncoprotein in hyperplastic endometrial polyps detected in two cats.
Misirlioglu D, Nak D, Ozyigit MO, Nak Y, Akkoc A
Journal of feline medicine and surgery 2009 Oct;11(10):885-8
Journal of feline medicine and surgery 2009 Oct;11(10):885-8
Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer.
Roepman P, Horlings HM, Krijgsman O, Kok M, Bueno-de-Mesquita JM, Bender R, Linn SC, Glas AM, van de Vijver MJ
Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Nov 15;15(22):7003-11
Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Nov 15;15(22):7003-11
Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH.
Joosse SA, van Beers EH, Tielen IH, Horlings H, Peterse JL, Hoogerbrugge N, Ligtenberg MJ, Wessels LF, Axwijk P, Verhoef S, Hogervorst FB, Nederlof PM
Breast cancer research and treatment 2009 Aug;116(3):479-89
Breast cancer research and treatment 2009 Aug;116(3):479-89
EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer.
Pietersen AM, Horlings HM, Hauptmann M, Langerød A, Ajouaou A, Cornelissen-Steijger P, Wessels LF, Jonkers J, van de Vijver MJ, van Lohuizen M
Breast cancer research : BCR 2008;10(6):R109
Breast cancer research : BCR 2008;10(6):R109
Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary.
Horlings HM, van Laar RK, Kerst JM, Helgason HH, Wesseling J, van der Hoeven JJ, Warmoes MO, Floore A, Witteveen A, Lahti-Domenici J, Glas AM, Van't Veer LJ, de Jong D
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008 Sep 20;26(27):4435-41
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008 Sep 20;26(27):4435-41
Evaluation of the value of frozen tissue section used as "gold standard" for immunohistochemistry.
Shi SR, Liu C, Pootrakul L, Tang L, Young A, Chen R, Cote RJ, Taylor CR
American journal of clinical pathology 2008 Mar;129(3):358-66
American journal of clinical pathology 2008 Mar;129(3):358-66
Estrogen receptor beta (ERbeta) in endometrial simple hyperplasia and endometrioid carcinoma.
Chakravarty D, Srinivasan R, Ghosh S, Rajwanshi A, Gopalan S
Applied immunohistochemistry & molecular morphology : AIMM 2008 Dec;16(6):535-42
Applied immunohistochemistry & molecular morphology : AIMM 2008 Dec;16(6):535-42
Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas.
Barbareschi M, Buttitta F, Felicioni L, Cotrupi S, Barassi F, Del Grammastro M, Ferro A, Dalla Palma P, Galligioni E, Marchetti A
Clinical cancer research : an official journal of the American Association for Cancer Research 2007 Oct 15;13(20):6064-9
Clinical cancer research : an official journal of the American Association for Cancer Research 2007 Oct 15;13(20):6064-9
The effect of maturation and age on oestrogen-induced functional hypertrophy of the female rabbit bladder.
Onal B, Levin RM, Kogan BA, Whitbeck C, Chichester P, Walebowa O, Mannikarottu AS
BJU international 2007 Mar;99(3):674-9
BJU international 2007 Mar;99(3):674-9
Altered expression of estrogen receptor alpha and beta in advanced gastric adenocarcinoma: correlation with prothymosin alpha and clinicopathological parameters.
Wang M, Pan JY, Song GR, Chen HB, An LJ, Qu SX
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2007 Mar;33(2):195-201
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2007 Mar;33(2):195-201
Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation.
Schmidt MK, Tollenaar RA, de Kemp SR, Broeks A, Cornelisse CJ, Smit VT, Peterse JL, van Leeuwen FE, Van't Veer LJ
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007 Jan 1;25(1):64-9
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007 Jan 1;25(1):64-9
Estrogen induced functional hypertrophy and increased force generation of the female rabbit bladder.
Lin AD, Levin R, Kogan B, Whitbeck C, Chichester P, Sokol R, Mannikarottu A
Neurourology and urodynamics 2006;25(5):473-9
Neurourology and urodynamics 2006;25(5):473-9
Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy.
Hannemann J, Kristel P, van Tinteren H, Bontenbal M, van Hoesel QG, Smit WM, Nooij MA, Voest EE, van der Wall E, Hupperets P, de Vries EG, Rodenhuis S, van de Vijver MJ
British journal of cancer 2006 Nov 20;95(10):1334-41
British journal of cancer 2006 Nov 20;95(10):1334-41
Overexpression of cyclins D1 and D3 during estrogen-induced breast oncogenesis in female ACI rats.
Weroha SJ, Li SA, Tawfik O, Li JJ
Carcinogenesis 2006 Mar;27(3):491-8
Carcinogenesis 2006 Mar;27(3):491-8
Antagonist-induced, activation function-2-independent estrogen receptor alpha phosphorylation.
Lipfert L, Fisher JE, Wei N, Scafonas A, Su Q, Yudkovitz J, Chen F, Warrier S, Birzin ET, Kim S, Chen HY, Tan Q, Schmidt A, Dininno F, Rohrer SP, Hammond ML, Rodan GA, Freedman LP, Reszka AA
Molecular endocrinology (Baltimore, Md.) 2006 Mar;20(3):516-33
Molecular endocrinology (Baltimore, Md.) 2006 Mar;20(3):516-33
Search for Hsp90 inhibitors with potential anticancer activity: isolation and SAR studies of radicicol and monocillin I from two plant-associated fungi of the Sonoran desert.
Turbyville TJ, Wijeratne EM, Liu MX, Burns AM, Seliga CJ, Luevano LA, David CL, Faeth SH, Whitesell L, Gunatilaka AA
Journal of natural products 2006 Feb;69(2):178-84
Journal of natural products 2006 Feb;69(2):178-84
The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study.
Akhan SE, Yavuz E, Tecer A, Iyibozkurt CA, Topuz S, Tuzlali S, Bengisu E, Berkman S
Gynecologic oncology 2005 Oct;99(1):36-42
Gynecologic oncology 2005 Oct;99(1):36-42
Abnormal morphology of the penis in male rats exposed neonatally to diethylstilbestrol is associated with altered profile of estrogen receptor-alpha protein, but not of androgen receptor protein: a developmental and immunocytochemical study.
Goyal HO, Braden TD, Williams CS, Dalvi P, Mansour MM, Mansour M, Williams JW, Bartol FF, Wiley AA, Birch L, Prins GS
Biology of reproduction 2004 May;70(5):1504-17
Biology of reproduction 2004 May;70(5):1504-17
Epithelioid trophoblastic tumor of the broad ligament: a case report and review of the literature.
Kuo KT, Chen MJ, Lin MC
The American journal of surgical pathology 2004 Mar;28(3):405-9
The American journal of surgical pathology 2004 Mar;28(3):405-9
Epithelioid trophoblastic tumor of the broad ligament: a case report and review of the literature.
Kuo KT, Chen MJ, Lin MC
The American journal of surgical pathology 2004 Mar;28(3):405-9
The American journal of surgical pathology 2004 Mar;28(3):405-9
Molecular mechanism of estrogen receptor (ER)alpha-specific, estradiol-dependent expression of the progesterone receptor (PR) B-isoform.
Flötotto T, Niederacher D, Hohmann D, Heimerzheim T, Dall P, Djahansouzi S, Bender HG, Hanstein B
The Journal of steroid biochemistry and molecular biology 2004 Feb;88(2):131-42
The Journal of steroid biochemistry and molecular biology 2004 Feb;88(2):131-42
The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma.
Guler G, Uner A, Guler N, Han SY, Iliopoulos D, Hauck WW, McCue P, Huebner K
Cancer 2004 Apr 15;100(8):1605-14
Cancer 2004 Apr 15;100(8):1605-14
Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
Beliakoff J, Bagatell R, Paine-Murrieta G, Taylor CW, Lykkesfeldt AE, Whitesell L
Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Oct 15;9(13):4961-71
Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Oct 15;9(13):4961-71
Simultaneous carcinoma of the endometrium and ovary vs endometrial carcinoma with ovarian metastases: a clinical and immunohistochemical determination.
Halperin R, Zehavi S, Hadas E, Habler L, Bukovsky I, Schneider D
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2003 Jan-Feb;13(1):32-7
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2003 Jan-Feb;13(1):32-7
Simultaneous carcinoma of the endometrium and ovary vs endometrial carcinoma with ovarian metastases: a clinical and immunohistochemical determination.
Halperin R, Zehavi S, Hadas E, Habler L, Bukovsky I, Schneider D
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2003 Jan-Feb;13(1):32-7
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2003 Jan-Feb;13(1):32-7
Characterization of mammary tumor cell lines from wild type and vitamin D3 receptor knockout mice.
Zinser GM, McEleney K, Welsh J
Molecular and cellular endocrinology 2003 Feb 28;200(1-2):67-80
Molecular and cellular endocrinology 2003 Feb 28;200(1-2):67-80
Characterization of mammary tumor cell lines from wild type and vitamin D3 receptor knockout mice.
Zinser GM, McEleney K, Welsh J
Molecular and cellular endocrinology 2003 Feb 28;200(1-2):67-80
Molecular and cellular endocrinology 2003 Feb 28;200(1-2):67-80
Expression of CYP3A4 in human breast tumour and non-tumour tissues.
Kapucuoglu N, Coban T, Raunio H, Pelkonen O, Edwards RJ, Boobis AR, Iscan M
Cancer letters 2003 Dec 8;202(1):17-23
Cancer letters 2003 Dec 8;202(1):17-23
Expression of CYP3A4 in human breast tumour and non-tumour tissues.
Kapucuoglu N, Coban T, Raunio H, Pelkonen O, Edwards RJ, Boobis AR, Iscan M
Cancer letters 2003 Dec 8;202(1):17-23
Cancer letters 2003 Dec 8;202(1):17-23
Breast hamartomas: clinicopathological and immunohistochemical studies of 24 cases.
Herbert M, Sandbank J, Liokumovich P, Yanai O, Pappo I, Karni T, Segal M
Histopathology 2002 Jul;41(1):30-4
Histopathology 2002 Jul;41(1):30-4
Breast hamartomas: clinicopathological and immunohistochemical studies of 24 cases.
Herbert M, Sandbank J, Liokumovich P, Yanai O, Pappo I, Karni T, Segal M
Histopathology 2002 Jul;41(1):30-4
Histopathology 2002 Jul;41(1):30-4
Immunohistochemical comparison of primary peritoneal and primary ovarian serous papillary carcinoma.
Halperin R, Zehavi S, Hadas E, Habler L, Bukovsky I, Schneider D
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 2001 Oct;20(4):341-5
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 2001 Oct;20(4):341-5
Immunohistochemical comparison of primary peritoneal and primary ovarian serous papillary carcinoma.
Halperin R, Zehavi S, Hadas E, Habler L, Bukovsky I, Schneider D
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 2001 Oct;20(4):341-5
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 2001 Oct;20(4):341-5
5alpha-reductases in human breast carcinoma: possible modulator of in situ androgenic actions.
Suzuki T, Darnel AD, Akahira JI, Ariga N, Ogawa S, Kaneko C, Takeyama J, Moriya T, Sasano H
The Journal of clinical endocrinology and metabolism 2001 May;86(5):2250-7
The Journal of clinical endocrinology and metabolism 2001 May;86(5):2250-7
Biophenotypes and survival of BRCA1 and TP53 deleted breast cancer in young women.
Querzoli P, Albonico G, di Iasio MG, Ferretti S, Rinaldi R, Cariello A, Pedriali M, Matteuzzi M, Maestri I, Nenci I
Breast cancer research and treatment 2001 Mar;66(2):135-42
Breast cancer research and treatment 2001 Mar;66(2):135-42
Biophenotypes and survival of BRCA1 and TP53 deleted breast cancer in young women.
Querzoli P, Albonico G, di Iasio MG, Ferretti S, Rinaldi R, Cariello A, Pedriali M, Matteuzzi M, Maestri I, Nenci I
Breast cancer research and treatment 2001 Mar;66(2):135-42
Breast cancer research and treatment 2001 Mar;66(2):135-42
Apolipoprotein E polymorphism and breast carcinoma: correlation with cell proliferation indices and clinical outcome.
Zunarelli E, Nicoll JA, Migaldi M, Trentini GP
Breast cancer research and treatment 2000 Oct;63(3):193-8
Breast cancer research and treatment 2000 Oct;63(3):193-8
Apolipoprotein E polymorphism and breast carcinoma: correlation with cell proliferation indices and clinical outcome.
Zunarelli E, Nicoll JA, Migaldi M, Trentini GP
Breast cancer research and treatment 2000 Oct;63(3):193-8
Breast cancer research and treatment 2000 Oct;63(3):193-8
Evidence of an estrogen receptor form devoid of estrogen binding ability in MCF-7 cells.
El Khissiin A, Journé F, Laïos I, Seo HS, Leclercq G
Steroids 2000 Dec;65(12):903-13
Steroids 2000 Dec;65(12):903-13
Evidence of an estrogen receptor form devoid of estrogen binding ability in MCF-7 cells.
El Khissiin A, Journé F, Laïos I, Seo HS, Leclercq G
Steroids 2000 Dec;65(12):903-13
Steroids 2000 Dec;65(12):903-13
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of Estrogen Receptor alpha (ER alpha) was performed by loading the indicated amounts of recombinant full-length human ER alpha (Product # A15674) and ER beta (Product # A15664) proteins, and 10 µL of PageRuler Prestained Protein Ladder (Product # 26616) per well onto a Novex® 4-20% Tris-Glycine polyacrylamide gel. Proteins were transferred to a PVDF membrane (Product # 88518) using the G2 Blotter (Product # 62288), and blocked with 5% milk in TBST for at least 1 hour at room temperature. ER alpha was detected at ~66 kD (left panel) using an ER alpha monoclonal antibody (Product # MA5-13304) at a dilution of 1:1000 in blocking buffer overnight at 4C on a rocking platform, followed by an HRP-conjugated goat anti-mouse IgG secondary antibody (Product # 31430) at a dilution of 1:40,000. Chemiluminescent detection was performed using SuperSignal West Pico (Product # 34080). Directly alongside the above blot, a second blot containing the same recombinant ER alpha and ER beta protein samples was probed with an ER-beta specific polyclonal antibody (Product # PA1-313, right panel) at a dilution of 1:2000 overnight at 4C, followed by an HRP-conjugated goat anti-rabbit IgG secondary antibody (Product # 31460) at a dilution of 1:40,000. Chemiluminescent detection was again performed using SuperSignal West Pico (Product # 34080).
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of Estrogen Receptor alpha (ER alpha) was performed by loading 20 µg of whole cell lysates (WCL) or nuclear extracts (NE) from the indicated breast cancer cell lines, and 10 µL of PageRuler Prestained Protein Ladder (Product # 26616) per well onto a Novex® 4-20% Tris-Glycine polyacrylamide gel. Proteins were transferred to a PVDF membrane (Product # 88518) using the G2 Blotter (Product # 62288), and blocked with 5% milk in TBST for at least 1 hour at room temperature. ER alpha was detected at ~66 kD (top panel) using an ER alpha monoclonal antibody (Product # MA5-13304) at a dilution of 1:1000 in blocking buffer overnight at 4C on a rocking platform, followed by an HRP-conjugated goat anti-mouse IgG secondary antibody (Product # 31430) at a dilution of 1:40,000. Chemiluminescent detection was performed using SuperSignal West Dura (Product # 34075). To check for equivalent protein loading in each lane, a duplicate blot was probed with an HDAC1 polyclonal antibody (Product # PA1-860, bottom panel) at a dilution of 1:1000 overnight at 4C, followed by an HRP-conjugated goat anti-rabbit IgG secondary antibody (Product # 31460) at a dilution of 1:40,000. Chemiluminescent detection was also performed using SuperSignal West Dura (Product # 34075).
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot of Estrogen Receptor using Estrogen Receptor Monoclonal Antibody (Product # MA5-13304) on MCF-7 Cells.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescent analysis of Estrogen Receptor (ER, green) in T47D and Hs 578T breast cancer cells. The cells were fixed with 4% paraformaldehyde for 15 minutes at room temperature, permeabilized with 0.1% Triton X-100 for 15 minutes at room temperature, and blocked with 0.3% BSA in PBS for at least 30 minutes at room temperature. Cells were stained with an ER alpha monoclonal antibody (Product # MA5-13304) at a dilution of 1:100 in blocking buffer overnight at 4C, and then incubated with a DyLight 488-conjugated goat anti-mouse IgG secondary antibody (Product # 35502) at a dilution of 1:500 for at least 1 hour at room temperature. Nuclei (blue) were stained with DAPI (Product # 62247). Images were taken on a Thermo Scientific ToxInsight Instrument at 20X magnification.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Formalin-fixed, paraffin-embedded human breast carcinoma stained with Estrogen Receptor antibody2 using peroxidase-conjugate and DAB chromogen. Note intense nuclear staining of tumor cells.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunoprecipitation of Estrogen Receptor using Estrogen Receptor Monoclonal Antibody (Product # MA5-13304) on denatured Human MCF-7 Cells.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 2 Nf1 deficiency induces ER + /PR + mammary tumors. We observed mammary tumors with diverse mammary histology in G0 - G2 animals. a Nf1 females and b Nf1 males developed mammary adenocarcinomas with mixed histology including acinar, cystic, papillary, ductal, and solid features. All images were taken at 100X magnification. c Immunostaining of Nf1 mammary tumors ( rNf1 #6) for estrogen receptor, progesterone receptor, HER2, Ki67, and pan-cytokeratin (AE1/AE3). All immunostaining images were taken at 200X magnification
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 1 ESR1 mutant models exhibited oestrogen-independent growth and metastatic propensity. a MTT growth assay of Tam and Ful-treated MCF-7 and b T47D cells. Percent survival is normalised to no treatment controls. Graphs represent mean + standard deviation ( N = 3 replicates) one-way ANOVA was used for statistical analysis. c MCF-7 cells were cultured in charcoal-stripped serum supplemented media, underwent whole cell lysis, and analysed by immunoblot for ER-regulated proteins (left). Values below PR, CCND1 and c-Jun represent normalised densitometry of each protein compared to GAPDH. PR was not detected in WT cells; thus, relative expression was normalised to Y537S cells. Cells were cultured in charcoal-stripped supplemented media and underwent cellular fractionation (right). Nuclear fraction is shown. d T47D cells were cultured in charcoal-stripped serum supplemented media and analysed by immunoblot for ER-regulated proteins (left). Values below PR, CCND1 and c-Jun represent normalised densitometry of each protein compared to GAPDH. PR was not detected in WT cells. Cells were cultured in charcoal-stripped supplemented media and underwent cellular fractionation (right). e Venn diagram of upregulated MSigDB Hallmark gene sets in MCF-7 ESR1 Y537S and LTED cells compared to MCF-7 ESR1 WT, and T47D ESR1 Y537S compared to T47D ESR1 WT. The numbers shown are of Hallmarks with a false discovery rate < 0.25. f In vivo individual tumour growth curves of MCF-7 ESR1 WT, ESR1 Y537S and
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 2 ESR1 mutations induced a global kinome reprogramming. a Flowchart demonstrating the total number of kinases captured in KiP experiment and the selection of kinases used to perform KEGG pathway analysis. Hyperactivated was defined as Y537S/WT >= 1.5-fold. Unique was defined as having corresponding peptide detection by MS in only MCF-7 ESR1 WT or MCF-7 ESR1 Y537S cells. b KEGG pathway analysis of the hyperactivated kinases in ESR1 Y537S cells. Analysis was performed using the DAVID Bioinformatics Functional Annotation Tool. c Y537S/WT quantitative ratio of kinases in KiP analysis categorised by RTKs, PI3K, and MAPK pathways. Red bars represent Y537S-unique activated kinases. d MCF-7 cells were cultured in charcoal-stripped serum-supplemented media and analysed by immunoblot for phosphorylated and total RON. Numbers below each protein represent normalised densitometry of each protein compared to GAPDH. e T47D cells were cultured in charcoal-stripped serum-supplemented media and analysed by immunoblot for phosphorylated and total RON. Numbers below each protein represent normalised densitometry of each protein compared to GAPDH. f MCF-7 cells were cultured in full serum-supplemented media and treated with BMS-777607/ASLAN002 (RONi) for 90 min and analysed by immunoblot for phosphorylated and total RON and IGF-1R. Numbers below each protein represent normalised densitometry of each protein compared to GAPDH. g MCF-7 cells were cultured in full serum-supplemented media and t
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 3 ET reduced RON/PI3K pathway activation. a Fold change of kinases in KiP analysis in MCF-7 Y537S cells after treatment with Tam. X -values represent fold change of Tam-treated Y537S cells compared to untreated Y537S cells. b MCF-7 cells were cultured in 10% FBS supplemented media and treated with 1 uM Tam and 1 uM Ful for 48 h. Immunoblot analysis of phosphorylated and total RON was performed. Numbers below each protein represent normalised densitometry of each protein compared to GAPDH. c MCF-7 cells were cultured in 10% FBS supplemented media and treated with Tam and Ful for 48 h. qRT-PCR analysis of RON was performed. Graphs represent mean + standard error of the mean ( N = 3 replicates). Two-way ANOVA was used for statistical analysis. d MCF-7 cells were cultured in 10% FBS supplemented media and treated with RONi for ninety minutes. Immunoblot analysis was performed for phosphorylated and total AKT and p44/42 MAPK. e MCF-7 cells were cultured in charcoal-stripped serum supplemented media and treated with RONi for 24 hours and ER transactivation assay was performed. Graphs represent mean + standard deviation ( N = 3 replicates). Student's t -test was used for statistical analysis. f MCF-7 cells were cultured in 10% FBS supplemented media and treated with 1 uM Tam and 1 uM Ful for 48 h. Immunoblot of phosphorylated and total AKT and p44/42 MAPK was performed. g T47D cells were cultured in 10% FBS supplemented media and treated with Tam and Ful for 48 h. Immunoblot of
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 3 MCF7-derived ducts grown in a mixed collagen:fibroblast matrix express lower levels of ER protein. MCF7-derived ducts were cultured alone or in co-culture with HMFs, treated with a vehicle control or 100 nM E2 for 24 hours. ( A ) Cultures were fixed and stained to visualize nuclei and ERalpha protein. Scale bar represents 100 mum. To quantify ER protein, the Hoescht stain was used to generate nuclear masks then ER expression was quantified within each nuclear mask. ( B ) Mean ER expression per condition was graphed to visualize ER protein changes within the entire population. A two-way ANOVA was run to evaluate interactions between conditions, followed by a Tukey's multiple comparison test to identify significant differences. ( C ) A density plot was created to show the frequency of individual cells (x-axis) that expressed various levels of ER protein (y-axis). *= vs. respective vehicle (p < 0.05) and ++= vs. respective monoculture (p < 0.05). Data is representative of three independent experiments.